Cancer News and Research

Latest Cancer News and Research

Olympus' ENDOEYE FLEX 3D articulating videoscope earns top honors at ATA Showcase

Olympus, a global technology leader in delivering innovative diagnostic and therapeutic solutions for medical and surgical procedures, among other core businesses, announced today that its ENDOEYE FLEX 3D articulating videoscope received top honors as the Breakthrough Technology of the Year.

From Evident Corporation - Life Sciences 6 Jun 2014

Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations (RMPs).

6 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

MolecularHealth launches innovative oncology program for employers

MolecularHealth announced today the official launch of MolecularHealth COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP.

6 Jun 2014

Golden Door introduces new online destination of goldendoor.com.

Golden Door, the globally renowned wellness resort is pleased to introduce the new online destination of goldendoor.com.

6 Jun 2014

Prostate biopsy method impacts cancer risk profile

Prostate cancers that are classified as “low risk” based on conventional prostate biopsy and histology are frequently found to be higher risk when assessed using the newer targeted biopsy method, US researchers have warned.

5 Jun 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

UST Global receives 'Group Application Services Supplier of the Year' award

UST Global, a leading global IT consulting firm for Global 1000 enterprises, was awarded 'Group Application Services Supplier of the Year' by Alliance Boots.

5 Jun 2014

Team Type 1 Foundation awards scholarships to student athletes with type 1 diabetes

The Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, empowerment and equal access to medicine for everyone affected by diabetes, will award $5,000 scholarships to seven student athletes for the 2014-15 academic year as part of the Foundation's inaugural "Global Ambassador Program" recognizing young, talented athletes with type 1 diabetes who are using their sport as a platform to inspire.

5 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Affymetrix, BioDiscovery launch new analysis software for cancer research

Affymetrix and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit.

5 Jun 2014

ASTRO issues new Model Policy for proton beam therapy

The American Society for Radiation Oncology (ASTRO) has issued a new Model Policy for proton beam therapy (PBT) that details which cancer diagnoses meet ASTRO's evidence-based standards and should be covered by private insurers and Medicare.

5 Jun 2014

Palliative support services help caregivers of patients with advanced cancer

Dartmouth researchers have found that those caring for patients with advanced cancer experienced reduced depression and felt less burdened by caregiving tasks when palliative support services were offered soon after the patient's diagnosis.

5 Jun 2014

Gamma and neutron imaging safe and effective in simulations

Gamma and neutron imaging offer possible improvements over existing techniques such as X-ray or CT, but their safety is not yet fully understood.

5 Jun 2014

Study reveals molecular mechanism of cell death

Researchers at VIB and Ghent University have unraveled the mechanism of necroptosis. This is a type of cell death that plays a crucial role in numerous diseases, from viral infections and loss of auditory nerve cells to multiple sclerosis, acute heart failure and organ transplantation.

5 Jun 2014